82 FR 10022 - Government-Owned Inventions; Availability for Licensing
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 26 (February 9, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 26 (February 9, 2017)
| Page Range | 10022-10023 | |
| FR Document | 2017-02674 |
[Federal Register Volume 82, Number 26 (Thursday, February 9, 2017)] [Notices] [Pages 10022-10023] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-02674] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning Description of Technology This technology relates to the field of radioactive, isotopically- labeled calcofluor derivatives and uses of such compounds to detect a broad spectrum of filamentous fungi including pathogenic species such as Aspergillus and Mucorales, by diagnostic imaging methods such as positron emission tomography (PET) scanning. Aspergillosis and other filamentous fungal infections are increasingly common fungal lung infection with high mortality rates (over 50%) in immune compromised patients, such as those receiving chemotherapy, stem cell/organ transplantation, or HIV patients. One- year survival of the infected patients ranges from 59% (organ transplant recipients) to as low as 25% (stem cell transplant recipients). Delayed diagnosis and therapy are likely to lead to poor outcomes and death. This disease is often first detected as nodules on CT scans. A diagnosis is typically made following invasive lung bronchoscopy or biopsy. However, as these patients are immunocompromised, these invasive procedures may themselves lead to significant complications and infections. Therefore, to enable timely treatment and minimize complications, there is a critical need for non- invasive means to detect and diagnose fungal infections. The calcofluor derivatives disclosed in the patent application may be utilized as imaging agents specific for fungal infections and could potentially become a standard, non-invasive procedure in the work-up of immunocompromised patients with lung infections. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial ApplicationsDiagnostics of Aspergillosis and other filamentous fungal infections. Competitive Advantages Non-invasive. [[Page 10023]] Low toxicity. Specific for Aspergillus. Development Stage In vivo data available (animal). Inventors: Peter R. Williamson (NIAID), Dale O. Kiesewetter (NIBIB), John C. Panepinto (University of Buffalo), and Jin Qiu (NIAID). Publications 1. Palmer GE, et al., The diverse roles of autophagy in medically important fungi, Autophagy. 2008 Nov; 4(8):982-8. [PMID 18927489] 2. Panepinto JC, et al., Deletion of the Aspergillus fumigatus gene encoding the Ras-related protein RhbA reduces virulence in a model of invasive pulmonary aspergillosis, Infect Immun. 2003 May; 71(5):2819- 26. [PMID 12704156] 3. Desoubeaux D, et al., Diagnosis of invasive pulmonary aspergillosis: Updates and recommendations, Med Mal Infect. 2014 Mar; 44(3):89-101. [PMID 24548415] Intellectual Property: HHS Reference Nos. E-449-2013/0,1--U.S. Provisional Application No. 61/894,754, filed October 23, 2013; PCT Application No. PCT/US2014/061917, filed October 23, 2014 (published as WO 2015/061540 on April 30, 2015); European Application No. 14800182.9, filed October 23, 2014 (pending); Australian Application No. 2014340035, filed October 23, 2014 (pending); Canadian Application No. 2927952, filed October 23, 2014; and U.S. Application No. 15/030,554, filed April 19, 2016 (pending). Licensing Contact: Dr. David Yang, 240-627-3413; [email protected]. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of this invention. For collaboration opportunities, please contact Dr. David Yang, 240- 627-3413; [email protected]. Dated: February 6, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017-02674 Filed 2-8-17; 8:45 am] BILLING CODE 4140-01-P
![10022 Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices
could disclose confidential trade secrets Training Review Branch, Division of Fishers Lane, Rockville, MD, 20852; tel.
or commercial property such as Extramural Activities, National Cancer 301–496–2644. A signed Confidential
patentable material, and personal Institute, NIH, 9609 Medical Center Drive, Disclosure Agreement will be required
Room 7W234, Rockville, MD 20892–9750,
information concerning individuals to receive copies of unpublished patent
240–276–6368, stoicaa2@mail.nih.gov.
associated with the grant applications/ applications.
Name of Committee: National Cancer
contract proposals, the disclosure of Institute Special Emphasis Panel; Cancer SUPPLEMENTARY INFORMATION:
which would constitute a clearly Center Support Grant. Technology description follows.
unwarranted invasion of personal Date: April 7, 2017.
privacy. Time: 1:00 p.m. to 3:00 p.m.
Small Molecule Imaging of Fungi by
Agenda: To review and evaluate grant Positron Emission Tomography
Name of Committee: National Cancer Scanning
Institute Special Emphasis Panel; Questions applications.
in Cancer System Biology. Place: National Cancer Institute Shady Description of Technology
Date: March 2, 2017. Grove, 9609 Medical Center Drive, Room
Time: 8:00 a.m. to 4:00 p.m. 7W030, Rockville, MD 20850 (Telephone This technology relates to the field of
Agenda: To review and evaluate grant Conference Call). radioactive, isotopically-labeled
applications. Contact Person: Caterina Bianco, MD, calcofluor derivatives and uses of such
Place: National Cancer Institute Shady Ph.D., Scientific Review Officer, Research compounds to detect a broad spectrum
Grove, 9609 Medical Center Drive, Room Programs Review Branch, Division of
of filamentous fungi including
2E908, Rockville, MD 20850. Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive, pathogenic species such as Aspergillus
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and Room 7W110, Bethesda, MD 20892–9750, and Mucorales, by diagnostic imaging
Training Review Branch, Division of 240–276–6459, biancoc@mail.nih.gov. methods such as positron emission
Extramural Activities, National Cancer (Catalogue of Federal Domestic Assistance tomography (PET) scanning.
Institute, NIH, 9609 Medical Center Drive, Program Nos. 93.392, Cancer Construction; Aspergillosis and other filamentous
Room 7W234, Bethesda, MD 20892–9750, 93.393, Cancer Cause and Prevention fungal infections are increasingly
240–276–6368, stoicaa2@mail.nih.gov. Research; 93.394, Cancer Detection and common fungal lung infection with high
Name of Committee: National Cancer Diagnosis Research; 93.395, Cancer mortality rates (over 50%) in immune
Institute Special Emphasis Panel; Tools for Treatment Research; 93.396, Cancer Biology compromised patients, such as those
Monitoring RNA. Research; 93.397, Cancer Centers Support;
receiving chemotherapy, stem cell/organ
Date: March 14, 2017. 93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health, transplantation, or HIV patients. One-
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant HHS) year survival of the infected patients
applications. ranges from 59% (organ transplant
Dated: February 3, 2017.
Place: National Cancer Institute Shady recipients) to as low as 25% (stem cell
Grove, 9609 Medical Center Drive, Room Melanie J. Pantoja, transplant recipients). Delayed
4W030, Rockville, MD 20850 (Telephone Program Analyst, Office of Federal Advisory diagnosis and therapy are likely to lead
Conference Call). Committee Policy. to poor outcomes and death. This
Contact Person: Jeffrey E. DeClue, Ph.D., [FR Doc. 2017–02621 Filed 2–8–17; 8:45 am] disease is often first detected as nodules
Scientific Review Officer, Research
Technology and Contract Review Branch,
BILLING CODE 4140–01–P on CT scans. A diagnosis is typically
Division of Extramural Activities, National made following invasive lung
Cancer Institute, NIH, 9609 Medical Center bronchoscopy or biopsy. However, as
Drive, Room 7W238, Bethesda, MD 20892– DEPARTMENT OF HEALTH AND these patients are
9750, 240–276–6371, decluej@nih.gov. HUMAN SERVICES immunocompromised, these invasive
Name of Committee: National Cancer procedures may themselves lead to
Institute Special Emphasis Panel; Co-Clinical National Institutes of Health
significant complications and
Imaging. infections. Therefore, to enable timely
Date: March 30, 2017. Government-Owned Inventions;
Availability for Licensing treatment and minimize complications,
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract there is a critical need for non-invasive
AGENCY: National Institutes of Health, means to detect and diagnose fungal
proposals.
Place: National Cancer Institute Shady HHS. infections.
Grove, 9609 Medical Center Drive, Room ACTION: Notice. The calcofluor derivatives disclosed
7W030, Rockville, MD 20850 (Telephone in the patent application may be
Conference Call). SUMMARY: The invention listed below is utilized as imaging agents specific for
Contact Person: Kenneth L. Bielat, Ph.D., owned by an agency of the U.S. fungal infections and could potentially
Scientific Review Officer, Research Government and is available for become a standard, non-invasive
Technology and Contract Review Branch, licensing to achieve expeditious
Division of Extramural Activities, National procedure in the work-up of
commercialization of results of immunocompromised patients with
Cancer Institute, NIH, 9609 Medical Center federally-funded research and
Drive, Room 7W244, Rockville, MD 20892– lung infections.
9750, 240–276–6373, bielatk@mail.nih.gov. development. Foreign patent This technology is available for
Name of Committee: National Cancer
applications are filed on selected licensing for commercial development
Institute Special Emphasis Panel; inventions to extend market coverage in accordance with 35 U.S.C. 209 and 37
Collaborative Consortia for the Study of HIV- for companies and may also be available CFR part 404, as well as for further
Associated Cancers (U54) RFA–CA–16–018. for licensing. development and evaluation under a
Date: April 5–6, 2017. FOR FURTHER INFORMATION CONTACT:
sradovich on DSK3GMQ082PROD with NOTICES
research collaboration.
Time: 8:00 a.m. to 5:00 p.m. Licensing information and copies of the
Agenda: To review and evaluate grant patent applications listed below may be Potential Commercial Applications
applications.
Place: Bethesda North Marriott Hotel &
obtained by communicating with the • Diagnostics of Aspergillosis and
Conference Center, 5701 Marinelli Road, indicated licensing contact at the other filamentous fungal infections.
North Bethesda, MD 20852. Technology Transfer and Intellectual
Property Office, National Institute of Competitive Advantages
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and Allergy and Infectious Diseases, 5601 • Non-invasive.
VerDate Sep<11>2014 18:11 Feb 08, 2017 Jkt 241001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\09FEN1.SGM 09FEN1](https://thefederalregister.org/doc/82_FR_10048/page/1.svg)
![Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices 10023
• Low toxicity. DEPARTMENT OF HEALTH AND 93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
• Specific for Aspergillus. HUMAN SERVICES
HHS)
Development Stage National Institutes of Health Dated: February 3, 2017.
• In vivo data available (animal). National Cancer Institute; Notice of Melanie J. Pantoja,
Inventors: Peter R. Williamson Closed Meetings Program Analyst, Office of Federal Advisory
Committee Policy.
(NIAID), Dale O. Kiesewetter (NIBIB), Pursuant to section 10(d) of the
[FR Doc. 2017–02615 Filed 2–8–17; 8:45 am]
John C. Panepinto (University of Federal Advisory Committee Act, as
Buffalo), and Jin Qiu (NIAID). BILLING CODE 4140–01–P
amended (5 U.S.C. App.), notice is
hereby given of meetings of the Board of
Publications
Scientific Counselors for Basic Sciences,
National Cancer Institute and the Board DEPARTMENT OF HEALTH AND
1. Palmer GE, et al., The diverse roles HUMAN SERVICES
of autophagy in medically important of Scientific Counselors for Clinical
fungi, Autophagy. 2008 Nov; 4(8):982–8. Sciences and Epidemiology, National
National Institutes of Health
[PMID 18927489] Cancer Institute.
The meetings will be closed to the National Institute of Allergy and
2. Panepinto JC, et al., Deletion of the public as indicated below in accordance
Aspergillus fumigatus gene encoding Infectious Diseases; Notice of Closed
with the provisions set forth in section
the Ras-related protein RhbA reduces Meeting
552b(c)(6), Title 5 U.S.C., as amended
virulence in a model of invasive for the review, discussion, and
pulmonary aspergillosis, Infect Immun. Pursuant to section 10(d) of the
evaluation of individual intramural
2003 May; 71(5):2819–26. [PMID Federal Advisory Committee Act, as
programs and projects conducted by the
12704156] amended (5 U.S.C. App.), notice is
National Cancer Institute, including
consideration of personnel hereby given of the following meeting.
3. Desoubeaux D, et al., Diagnosis of
invasive pulmonary aspergillosis: qualifications and performance, and the The meeting will be closed to the
Updates and recommendations, Med competence of individual investigators, public in accordance with the
Mal Infect. 2014 Mar; 44(3):89–101. the disclosure of which would provisions set forth in sections
[PMID 24548415] constitute a clearly unwarranted 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
invasion of personal privacy. as amended. The contract proposals and
Intellectual Property: HHS Reference the discussions could disclose
Name of Committee: Board of Scientific
Nos. E–449–2013/0,1—U.S. Provisional Counselors for Clinical Sciences and confidential trade secrets or commercial
Application No. 61/894,754, filed Epidemiology, National Cancer Institute. property such as patentable material,
October 23, 2013; PCT Application No. Date: March 6, 2017. and personal information concerning
PCT/US2014/061917, filed October 23, Time: 8:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate personal
individuals associated with the contract
2014 (published as WO 2015/061540 on proposals, the disclosure of which
qualifications and performance, and
April 30, 2015); European Application would constitute a clearly unwarranted
competence of individual investigators.
No. 14800182.9, filed October 23, 2014 Place: National Institutes of Health, 31 invasion of personal privacy.
(pending); Australian Application No. Center Drive, Building 31, C–Wing, 6th Floor,
2014340035, filed October 23, 2014 Conference Room 6, Bethesda, MD 20892. Name of Committee: National Institute of
Contact Person: Brian E. Wojcik, Ph.D., Allergy and Infectious Diseases Special
(pending); Canadian Application No.
Senior Review Administrator, Institute Emphasis Panel; NIAID Peer Review Meeting.
2927952, filed October 23, 2014; and
Review Office, Office of the Director, Date: March 6, 2017.
U.S. Application No. 15/030,554, filed National Cancer Institute, National Institutes Time: 1:00 p.m. to 3:00 p.m.
April 19, 2016 (pending). of Health, 9609 Medical Center Drive, Room Agenda: To review and evaluate contract
Licensing Contact: Dr. David Yang, 3W414, Bethesda, MD 20892, 240–276–5664, proposals.
240–627–3413; polung.yang@nih.gov. wojcikb@mail.nih.gov. Place: National Institutes of Health, 5601
Name of Committee: Board of Scientific Fishers Lane, Rockville, MD 20892
Collaborative Research Opportunity: Counselors for Basic Sciences, National (Telephone Conference Call).
The National Institute of Allergy and Cancer Institute. Contact Person: Kelly Y. Poe, Ph.D.,
Infectious Diseases is seeking statements Date: March 7, 2017.
Scientific Review Office, Scientific Review
of capability or interest from parties Time: 9:00 a.m. to 12:15 p.m.
Agenda: To review and evaluate personal Program, Division of Extramural Activities,
interested in collaborative research to Room 3F40B, National Institutes of Health,
further develop, evaluate or qualifications and performance, and
competence of individual investigators. NIAID, 5601 Fishers Lane, MSC 9823,
commercialize for development of this Place: National Institutes of Health, 31 Bethesda, MD 20892–9823, (240) 669–5036,
invention. For collaboration Center Drive, Building 31, C–Wing, 6th Floor, poeky@mail.nih.gov.
opportunities, please contact Dr. David Conference Room 6, Bethesda, MD 20892. (Catalogue of Federal Domestic Assistance
Yang, 240–627–3413; polung.yang@ Contact Person: Mehrdad Tondravi, Ph.D., Program Nos. 93.855, Allergy, Immunology,
nih.gov. Chief, Institute Review Office, Office of the
and Transplantation Research; 93.856,
Director, National Cancer Institute, National
Dated: February 6, 2017. Institutes of Health, 9609 Medical Center Microbiology and Infectious Diseases
Suzanne Frisbie, Drive, Room 3W–302, Bethesda, MD 20892, Research, National Institutes of Health, HHS)
sradovich on DSK3GMQ082PROD with NOTICES
240–276–5664, tondravim@mail.nih.gov. Dated: February 3, 2017.
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute (Catalogue of Federal Domestic Assistance Natasha M. Copeland,
of Allergy and Infectious Diseases. Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention Program Analyst, Office of Federal Advisory
[FR Doc. 2017–02674 Filed 2–8–17; 8:45 am] Committee Policy.
Research; 93.394, Cancer Detection and
BILLING CODE 4140–01–P Diagnosis Research; 93.395, Cancer [FR Doc. 2017–02620 Filed 2–8–17; 8:45 am]
Treatment Research; 93.396, Cancer Biology BILLING CODE 4140–01–P
Research; 93.397, Cancer Centers Support;
VerDate Sep<11>2014 18:11 Feb 08, 2017 Jkt 241001 PO 00000 Frm 00041 Fmt 4703 Sfmt 9990 E:\FR\FM\09FEN1.SGM 09FEN1](https://thefederalregister.org/doc/82_FR_10048/page/2.svg)
Document Created: 2017-02-09 01:02:41
Document Modified: 2017-02-09 01:02:41
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. | |
| FR Citation | 82 FR 10022 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR